US5196195A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of arginase to control nitric oxide formation
Assignee: Cornell Research Foundation Inc
•
Filing: 1990-03-27
•
Granted: 1993-03-23
•
Expires: 2010-03-27
Abstract
Abstract Reducing plasma levels of endogenous arginine by parenteral administration of arginine depleting agent reduces nitric oxide levels and results in blood pressure increase. Preferably arginase is administered intravenously to raise blood pressure. The arginase can be administered in conjunction with arginine antagonists to potentiate the effect of these. Duration of action and avoidance of antigenicity may be obtained by use in conjunction with a carrier or modifier.
Inventors
- 👤 Owen W. Griffith
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 08:13
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/50
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
43 words
A method for limiting nitric oxide production in a subject in need of such limiting, said method comprising parenterally administering an amount of a plasma arginine depleting enzyme to effect reduction of plasma level of arginine to a nitric oxide production limiting level.
Claim 2
Independent Claim
43 words
A method for limiting nitric oxide production in a subject in need of such limiting, said method comprising parenterally administering an amount of a plasma arginine depleting enzyme to effect reduction of plasma level of arginine to a nitric oxide production limiting level.
Claim 3
Dependent Claim
25 words
The method of claim 1 wherein the arginine depleting agent is an enzyme selected from the group consisting of arginase, arginine decarboxylase and arginine deiminase.
Claim 4
Dependent Claim
10 words
The method of claim 1 wherein said agent is arginase.
Claim 5
Dependent Claim
31 words
The method of claim 3 wherein the nitric oxide production limited is that by endothelial cells and said amount of agent is such as to cause increase in diastolic blood pressure.
Claim 6
Dependent Claim
11 words
The method of claim 3 wherein the arginase is administered intravenously.
Claim 7
Dependent Claim
44 words
The method of claim 3 wherein the arginase is administered in a nitric oxide production reducing amount together with an arginine antagonist, the amount of said antagonist being less than a nitric oxide production inhibiting amount of said antagonist in the absence of arginase.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-03-22 | 1996-09-21 | 1997-03-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-03-22 | 2000-09-21 | 2001-03-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-03-22 | 2004-09-21 | 2005-03-23 | $7700.00 | Window Closed / Lapsed |